217 related articles for article (PubMed ID: 37179465)
1. Pharmacotherapy of heart failure A.D. 2023. Expert opinion of Working Group on Cardiovascular Pharmacotherapy, Polish Cardiac Society.
Kasprzak JD; Gorczyca-Głowacka I; Sobczak-Kaleta M; Barylski M; Drożdż J; Filipiak KJ; Kapłon-Cieślicka A; Lelonek M; Mamcarz A; Ochijewicz D; Ryś-Czaporowska A; Starzyk K; Szymański FM; Wełnicki M; Wożakowska-Kapłon B
Kardiol Pol; 2023; 81(5):537-556. PubMed ID: 37179465
[TBL] [Abstract][Full Text] [Related]
2. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
Rohde LE; Claggett BL; Wolsk E; Packer M; Zile M; Swedberg K; Rouleau J; Pfeffer MA; Desai AS; Lund LH; Kober L; Anand I; Merkely B; Senni M; Shi V; Rizkala A; Lefkowitz M; McMurray JJV; Solomon SD
Circ Heart Fail; 2021 Mar; 14(3):e008052. PubMed ID: 33706551
[TBL] [Abstract][Full Text] [Related]
3. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
4. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
[TBL] [Abstract][Full Text] [Related]
6. Individualizing the treatment of patients with heart failure with reduced ejection fraction: a journey from hospitalization to long-term outpatient care.
Escobar C; Luis-Bonilla J; Crespo-Leiro MG; Esteban-Fernández A; Farré N; Garcia A; Nuñez J
Expert Opin Pharmacother; 2022 Oct; 23(14):1589-1599. PubMed ID: 35995759
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacological therapy of heart failure with reduced ejection fraction].
Wieser M; Rhyner D; Martinelli M; Suter T; Schnegg B; Bösch C; Wigger O; Dobner S; Hunziker L
Ther Umsch; 2018 Sep; 75(3):180-186. PubMed ID: 30145973
[TBL] [Abstract][Full Text] [Related]
8. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV
Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological treatment options for heart failure with reduced ejection fraction: A 2022 update.
Hellenkamp K; Nolte K; von Haehling S
Expert Opin Pharmacother; 2022 Apr; 23(6):673-680. PubMed ID: 35260016
[TBL] [Abstract][Full Text] [Related]
10. Insights into implementation of sacubitril/valsartan into clinical practice.
Martens P; Beliën H; Dupont M; Mullens W
ESC Heart Fail; 2018 Jun; 5(3):275-283. PubMed ID: 29464879
[TBL] [Abstract][Full Text] [Related]
11. The effect of sacubitril / valsartan on the occurrence of ventricular arrhythmia and the risk of sudden cardiac death in patients with chronic heart failure with reduced left ventricular ejection fraction. Expert opinion of the Heart Rhythm and Heart Failure Sections of the Polish Cardiac Society.
Grabowski M; Ozierański K; Balsam P; Dąbrowski R; Farkowski MM; Gackowski A; Jędrzejczyk-Patej E; Kalarus Z; Leszek P; Nessler J; Sterliński M; Opolski G; Przybylski A
Kardiol Pol; 2019 Oct; 77(10):987-993. PubMed ID: 31527563
[TBL] [Abstract][Full Text] [Related]
12. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
[TBL] [Abstract][Full Text] [Related]
13. A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction.
Nguyen E; Weeda ER; White CM
J Clin Pharmacol; 2016 Aug; 56(8):936-47. PubMed ID: 26626162
[TBL] [Abstract][Full Text] [Related]
14. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
[TBL] [Abstract][Full Text] [Related]
15. Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure.
Iovanovici DC; Bungau SG; Vesa CM; Moisi M; Babes EE; Tit DM; Horvath T; Behl T; Rus M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232632
[TBL] [Abstract][Full Text] [Related]
16. Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure.
Marques da Silva P; Aguiar C
Rev Port Cardiol; 2017 Sep; 36(9):655-668. PubMed ID: 28844335
[TBL] [Abstract][Full Text] [Related]
17. Neurohormonal modulation: The new paradigm of pharmacological treatment of heart failure.
Silva-Cardoso J; Brás D; Canário-Almeida F; Andrade A; Oliveira L; Pádua F; Fonseca C; Bragança N; Carvalho S; Soares R; Santos JF
Rev Port Cardiol (Engl Ed); 2019 Mar; 38(3):175-185. PubMed ID: 31029493
[TBL] [Abstract][Full Text] [Related]
18. Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis.
Aimo A; Pateras K; Stamatelopoulos K; Bayes-Genis A; Lombardi CM; Passino C; Emdin M; Georgiopoulos G
Cardiovasc Drugs Ther; 2021 Oct; 35(5):1067-1076. PubMed ID: 33074526
[TBL] [Abstract][Full Text] [Related]
19. Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan.
Liu RC
Am J Cardiovasc Drugs; 2018 Dec; 18(6):473-482. PubMed ID: 29850980
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
